Acesso Livre 1

FEBRE AMARELA

(1)
LING, Y. et al. Yellow fever in a worker returning to China from Angola, March 2016. Emerging infectious diseases, Atlanta, v. 22, n. 7, p. 1318, Jul. 2016.

Leia o artigo

Acesso Livre 2

(2)
CHAN, M. Yellow fever: the resurgence of a forgotten disease.Lancet, London, v. 387, n. 10034, p. 2165-2166, May, 2016 .

Leia o artigo

(3)
YELLOW fever: a global reckoning.Lancet, London, v. 387, n. 10026, p. 1348, Apr. , 2016 .

Leia o artigo

(4)
LUCEY, D. ; GOSTIN, L. O. A. Yellow Fever Epidemic: A New Global Health Emergency? JAMA, Chicago, v. 5, n. 24, p. 2661-2662, Jun. 2016.

Leia o artigo

(5)
BUTLER, D. Fears rise over yellow fever's next move. Nature, London, v. 532, n. 7598, p.155-156, Apr.2016.

Leia o artigo

(6)
WIETEN. R. W. et al. A single 17d yellow fever vaccination provides lifelong immunity; characterization of yellow-fever-specific neutralizing antibody and t-cell responses after vaccination.PLoS One, San Francisco, v.11, n. 3, e0149871, 2016.

Leia o artigo

(7)
CAVALCANTE, K. R. L. J. ; TAUIL, P. L.. Características epidemiológicas da febre amarela no Brasil, 2000-2012. Epidemiologia e serviço de saúde, Brasília, v. 25, n. 1, p. 11-20, jan.-mar. 2016.

Leia o artigo

(8)
BASSI, M. R. et al. Vaccination with replication deficient adenovectors encoding yf-17d antigens induces long-lasting protection from severe yellow fever virus infection in mice.PLoS Neglected Tropical Disease, San Francisco, v. 10, n. 2, e0004464, Feb. 2016 .

Leia o artigo

(9)
BARRETT , A.D.T. Yellow fever in Angola and Beyond — the problem of vaccine Supply and demand. New England Journal of Medicine, Boston, v. 375 n.4, p. 301-303, Jul. 2016.

Leia o artigo

(10)
CHIN, B. S. et al. Travel pattern and prescription analysis at a single travel clinic specialized for yellow fever vaccination in South Korea. Infection & Chemotherapy, v.48, n. 1, p.20-30, Mar. 2016.

Leia o artigo